Key result
Bivalirudin use in real-world patients with STEMI undergoing primary PCI resulted in a 30-day death rate of 2.1%, major bleeding in 1.5%, and no acute stent thrombosis.
Observational (n=678)
Yes
In a real-world registry of STEMI patients undergoing primary PCI, bivalirudin use was associated with low rates of 30-day adverse ischemic and bleeding events.
Supports bivalirudin in STEMI PCI with low events; leaves open need for randomized confirmation.
BACKGROUND: The effectiveness of bivalirudin in patients undergoing percutaneous coronary intervention for acute myocardial infarction has been tested in clinical trials, but its use in a real-world scenario has never been reported. METHODS: From the total number of patients enrolled in the EUROVISION registry, 678 subjects affected by ST-elevation myocardial infarction were selected and included in the analysis. Posology and usage patterns of bivalirudin, as evaluated by dose and time of drug bolus and infusion administered, were evaluated. The 30-day outcome has been assessed by efficacy and safety endpoints. RESULTS: All patients received an initial intravenous bolus of bivalirudin (0.70±0.25 mg/kg) followed by an infusion (1.58±0.47 mg/kg/h; duration: 60 [30, 107] min) in 99.3% of cases. An additional bolus (0.49±0.06 mg/kg) was administered in 9.3% of patients. Bivalirudin infusion was prolonged after procedure in 62.2%. Death occurred in 2.1% of patients, non-fatal myocardial reinfarction in 0.3%, unplanned revascularization in 0.6% and non-fatal stroke in 0.4%. Acute stent thrombosis was not observed. Major bleeding occurred in 1.5% of patients. CONCLUSIONS: Bivalirudin usage in the setting of primary PCI provided excellent results in terms of 30-day outcome even in a real-world population.
No takes yet. Share an insight, caveat, or question.
Limbruno et al. (2014) conducted an observational in ST-elevation myocardial infarction (n=678). Bivalirudin was evaluated on 30-day efficacy and safety endpoints. Bivalirudin use in real-world patients with STEMI undergoing primary PCI resulted in a 30-day death rate of 2.1%, major bleeding in 1.5%, and no acute stent thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: